|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROSCIENCE |
1 Departments of Pharmacology and
4 Chemistry, Emory University, Atlanta, GA 30322, USA
2 Department of Molecular Physiology and Biophysics, Vanderbilt University, 465 21st Avenue S, MRB III Room 7124, Nashville, TN 37232, USA
3 Department of Pharmacology and Toxicology and
5 Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23298, USA
6 Department of Pharmacology, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA
We have compared the potencies of structurally distinct channel blockers at recombinant NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D receptors. The IC50 values varied with stereochemistry and subunit composition, suggesting that it may be possible to design subunit-selective channel blockers. For dizocilpine (MK-801), the differential potency of MK-801 stereoisomers determined at recombinant NMDA receptors was confirmed at native receptors in vitro and in vivo. Since the proton sensor is tightly linked both structurally and functionally to channel gating, we examined whether blocking molecules that interact in the channel pore with the gating machinery can differentially sense protonation of the receptor. Blockers capable of remaining trapped in the pore during agonist unbinding showed the strongest dependence on extracellular pH, appearing more potent at acidic pH values that promote channel closure. Determination of pKa values for channel blockers suggests that the ionization of ketamine but not of other blockers can influence its pH-dependent potency. Kinetic modelling and single channel studies suggest that the pH-dependent block of NR1/NR2A by (–)MK-801 but not (+)MK-801 reflects an increase in the MK-801 association rate even though protons reduce channel open probability and thus MK-801 access to its binding site. Allosteric modulators that alter pH sensitivity alter the potency of MK-801, supporting the interpretation that the pH sensitivity of MK-801 binding reflects the changes at the proton sensor rather than a secondary effect of pH. These data suggest a tight coupling between the proton sensor and the ion channel gate as well as unique subunit-specific mechanisms of channel block.
(Received 14 November 2006;
accepted after revision 8 February 2007;
first published online 15 February 2007)
Corresponding author S. Dravid: Department of Pharmacology, Emory University School of Medicine, Rollins Research Centre, 1510 Clifton Road, Atlanta, GA 30322-3090, USA. Email: smdravid{at}pharm.emory.edu
Related Article
J. Physiol. 2007 581: 1-2.
This article has been cited by other articles:
![]() |
S. M. Dravid, A. Prakash, and S. F. Traynelis Activation of recombinant NR1/NR2C NMDA receptors J. Physiol., September 15, 2008; 586(18): 4425 - 4439. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, C. Z. Wang, J. Liu, N. C. Anastasio, and K. M. Johnson Lithium Protection of Phencyclidine-Induced Neurotoxicity in Developing Brain: The Role of Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 838 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hevers, S. H. Hadley, H. Luddens, and J. Amin Ketamine, But Not Phencyclidine, Selectively Modulates Cerebellar GABAA Receptors Containing {alpha}6 and {delta} Subunits J. Neurosci., May 14, 2008; 28(20): 5383 - 5393. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-R. Chang and C.-C. Kuo The Activation Gate and Gating Mechanism of the NMDA Receptor J. Neurosci., February 13, 2008; 28(7): 1546 - 1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Wrighton, E. J. Baker, P. E. Chen, and D. J. A. Wyllie Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes J. Physiol., January 1, 2008; 586(1): 211 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kohr NMDA receptor antagonists: tools in neuroscience with promise for treating CNS pathologies J. Physiol., May 15, 2007; 581(1): 1 - 2. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |